《静脉注射免疫球蛋白在血液系统疾病中应用的中国专家共识》
Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases.
作者信息
Guo Zhi, Zhu Jie, Wang Jun, Wang Liang, Tang Feifei, Huang Huiqiang, Xia Zhongjun, Liu Liqiong, Wang Danyu, Zhong Nan, Zhou Huanhuan, Zhou Zhaogui, Dai Wei, Xu Xiaojun, Zhou Hao, Deng Lijuan, Meng Jingye, Sun Zhiqiang, Shao Liang, Cao Yu J, Liu Yansong, Qu Rong, Li Guowei, Chen Peng, Zhang Hongyan, Liang Jing, Li Yuhua, Liu Jiajun, Xu Zishan, Sung Inda Soong, Xiang Xiaochen, Wu Qingming, Wang Qiang
机构信息
Department of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China.
Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Medical College, Wuhan University of Science and Technology, Wuhan, China.
出版信息
Front Med (Lausanne). 2025 Apr 1;12:1544025. doi: 10.3389/fmed.2025.1544025. eCollection 2025.
Intravenous immunoglobulin (IVIG), first developed for the treatment of patients with antibody deficiencies, is now widely used in clinical practice, especially in hematological and immune system diseases, and its application in hematological oncology chemotherapy, cellular immunotherapy and hematopoietic stem cell transplantation (HSCT) is becoming more and more common. The Chinese Collaborative Group for Infection Immunology and Microecology Research Translation Collaborative Group organized relevant experts to discuss and propose the "Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases," which was formulated based on the progress of research on the application of IVIG in blood diseases, and provides a basis for the standardization of the use of IVIG in hematologic disorders.
静脉注射免疫球蛋白（IVIG）最初是为治疗抗体缺陷患者而研发的，如今在临床实践中广泛应用，尤其是在血液学和免疫系统疾病方面，其在血液肿瘤化疗、细胞免疫治疗和造血干细胞移植（HSCT）中的应用也越来越普遍。中国感染免疫与微生态研究翻译协作组组织相关专家进行讨论，提出了《静脉注射免疫球蛋白在血液系统疾病中应用的中国专家共识》，该共识基于IVIG在血液疾病应用研究的进展而制定，为血液系统疾病中IVIG使用的规范化提供了依据。
Zotero 插件